JSMC
ITCI

Jess S. Morgan & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jess S. Morgan & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,500
Closed -$223K – 47
2019
Q4 		$223K Buy
+6,500
New +$78K 0.22% 38

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jess S. Morgan & Co's ITCI Position: Q1 2020 in Review

Jess S. Morgan & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 6,500 shares — an estimated $223K sold.

Jess S. Morgan & Co first reported a position in ITCI in Q4 2019 and held it in 1 quarter. The position peaked at $223K in Q4 2019. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Jess S. Morgan & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • Jess S. Morgan & Co sold 6,500 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $223K.
  • Jess S. Morgan & Co first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 1 quarter.
  • Jess S. Morgan & Co's Intra-Cellular Therapies Inc. position peaked at $223K in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Jess S. Morgan & Co's 13F filing for Q1 2020, filed 29 Nov 2021.